Fresh analysis suggests that patients who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional diet and exercise regimens.
Findings released in a major health publication shows that while obese individuals frequently drop about a fifth of their body weight while using the jabs, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these treatments must be informed of the potential of quick rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment mass within about a year and a half.
Analyzing Therapies
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with older methods.
Scientists point out that people who shed pounds through diet and exercise usually see a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Doctors believe the way of the injections is key to understanding the amplified weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
The NHS advise the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the high risk of relapse, the therapy is often life-long.
This opinion is echoed by pharmaceutical companies, who say that the results "underscore the long-term nature of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have stopped the medication explain a intense resurgence of appetite.
"I experienced a switch that goes on and I was suddenly ravenous," said a patient.
The struggle is worsened if individuals have not developed sustainable dietary or behavioural changes during treatment.
Widespread Use
Figures suggest that millions of adults in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Use is more common among women than men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, researchers emphasize that while these medications are powerful agents for shedding pounds, they are not a permanent solution and long-term success hinges on ongoing lifestyle changes.
